Latest Conference Articles

Darrell Kirch, MD, spoke at the APA’s annual meeting about the impact physician burnout has had and what can be done to address it and to improve clinician well-being.

Mayumi Okuda, MD, talked about what clinicians need to be doing and aware of in the identification of patients experiencing intimate partner violence.

Firearm use in the not guilty by reason of insanity population is more closely related to substance use and personality disorder than psychotic or mood disorders.

The associated PTSD comorbidities represent a significant public health problem that’s concomitant with increased disease burden and mortality.

Mayumi Okuda, MD, discussed Columbia's Chapman Perelman Domestic Violence Initiative, a program designed to help victims of abuse get the help and resources they need on their home turf.

The use of electroconvulsive therapy in patients with bipolar depression resulted in higher remission rates while showing similar response rates to unipolar major depression.

The algorithm is intended to help prevent mistakes caused by a slew of issues, from burnout at the end of a long day to overconfidence in decision-making.

Alan S. Brown, MD, FNLA, FACC, FAHA is a Cardiologist at Advocate Lutheran General Hospital and the President-Elect of the National Lipid Association (NLA). While at the NLA’s 2018 Scientific Sessions in Las Vegas, Nevada, he explained the connection between hypertriglyceridemia and FCS.

Alan S. Brown, MD, FNLA, FACC, FAHA, reviews emerging treatments and research for familial chylomicronemia syndrome (FCS).

Nanophotoswitches have demonstrated promising results in rats. Will they one day improve transduction in damaged eyes, and restore lost vision in humans?

The burden of ophthalmic disease is rising. How can ophthalmologists rise to meet it?

Intravitreal aflibercept injection showed early signs of activity for patients with moderately severe to severe nonproliferative diabetic retinopathy.

James J. Maciejko, MS, PhD, FACC, stresses the importance of rare disease awareness among physicians for proper diagnosis and treatment.

This past year, James A. Underberg, MD, MS, FACPM, FACP, FASPC, FNLA, President of the National Lipid Association (NLA), outlines familial chylomicronemia syndrome (FCS) and the need for treatments, which may not be far.

75% of patients with newly-diagnosed, treatment naïve DME received no treatment within 1 year of diagnosis.

At the National Lipid Association's (NLA) 2018 Scientific Sessions in LAs Vegas, NV, Wahida Karmally, MS, RD, CDE, explains the importance of nutrition and support in patients with familial chylomicronemia syndrome (FCS) and the emotional stress a strict, regimented diet can have on patients.

The novel immune-based treatment IMCgp100 demonstrated a 1-year survival rate of 73% for patients with heavily pretreated, advanced uveal melanoma.

Voretigene neparvovec demonstrated sustained improvements in vision for patients with biallelic RPE65-mutation–associated inherited retinal disease.

Outcomes for patients with nAMD in the real-world were inferior to randomized controlled trials due to significant undertreatment.

Researchers hypothesized that making eye care screens free also reduced perceived value of the services.

Genentech's global head of Neuroscience clinical development detailed the company's commitment to treating the progressive form of multiple sclerosis.

An automated artificial intelligence-based system was approximately 70% accurate at predicting optimal retreatment intervals for nAMD.

The majority of eyes treated in the DRCR Protocol S study had resolved, stable or improved NV at each follow-up visit.

Brolucizumab, which could be given every 12 weeks, showed non-inferior improvements in BCVA when compared with aflibercept every 8 weeks.

Use of a 0.18 mg fluocinolone acetonide intravitreal insert effectively lowered the rate of uveitis recurrences and cumulative total recurrent episodes.

The algorithm identified PPL-HMA in 20% of eyes and was associated with a 2-3 fold increased risk of DR progression, development of PDR and receipt of intravitreal injections over 4 years.

The deep learning algorithm was tested on 71,000 images, and offers the potential to significantly increase the speed at which DR can be identified.

Clinical and biochemical assessments of LPL FCS and non-LPL FCS genes.

FCS community highlights clinical presentation and lifestyle.

Eyes that received only anti-VEGF experienced significantly worse visual acuity from initial visit to final visit.